Sun Pharmaceuticals Ltd. is a leading pharma company in India. It was established in 1983 with only 5 products to treat psychiatry ailments. Mergers with the Caraco Pharm Labs (Detroit, US) and Halol based plant (UKMHRA & USFDA approved) were some of the important steps towards its globalization.
Sun Pharma has its corporate office in Mumbai, a research campus in Baroda and a research center in Mumbai. It has 15 manufacturing plants in 3 continents. It is mainly a dosage form company with 84% of sales from prescription products and 16% of sales from APIs. Sun Pharmaceuticals Ltd. manufactures specialty pharmaceuticals and active pharmaceuticals ingredients.
It has a brand name in the chronic therapy areas like gastroenterology, respiratory, cardiology, neurology, psychiatry and diabetology. Monotrate was among the earliest products of the company and since then it is the largest selling product of the company.
There are about 5000 people across the Sun Pharmaceutical group of companies. There are about 500 scientists working in research, 2500 people in sales and marketing (in India), and 260 in international markets other than the US.
The Board of Directors comprises of the following members:
Dilip S. Shanghvi: Chairman and Managing Director
Sudhir V. Valia: Executive Director
Sailesh T. Desai: Executive Director
Hasmukh S. Shah: Non-Executive Independent Director
Keki M. Mistry: Non-Executive Independent Director
Ashwin Dani: Non-Executive Independent Director
S. Mohandchand Dadha: Non-Executive Independent Director
Formulations: The product portfolio of Sun Pharmaceutical Ltd. ranges from injections, solid oral dosage forms (tablets, capsules), aerosols, nasal sprays, dry powder inhalers, creams and ointments to technically complex preparations like liposome based products, time release / controlled release preparations, Depot preparations and melt tabs.
API: Sun pharma’s API plants are well designed, large and have compliance with the international requirements. Flexible product mix and quick product change over is supported by the infrastructure, processes and system at the plants.
Company’s API plant at Ahmednagar has USFDA, European, OHSAS 18001, ISO 9002 and ISO 14001 approvals and the plant at Panoli holds USFDA, Australian TGA, and ISO 9002 approvals.
Both the plants have dedicated manufacturing areas for complex APIs such as peptides, anticancer, sex hormones and steroids. On an average the company adds about 15-20 APIs per year.
Andheri – Kurla Road, Andheri (E),
Mumbai – 400 059.